Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); ...
On 4 May 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...
Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for ...
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth ...
WVTM Channel 13 on MSN
Drier in Alabama to end the week with scattered storms at times over the weekend
Drier in Alabama to end the week with scattered storms at times over the weekend ...
The company is successfully transitioning from simple data licensing to strategic AI collaboration, with partners ...
Companion diagnostic (CDx) tests play a critical role in personalising care by identifying optimal targeted therapies for patients based on their cancer’s unique genetic profile. The Food & Drug ...
Guardant Health, Inc. (NASDAQ: GH) shares prospered Monday. The company, a leading precision oncology concern, today ...
The Developed World Bond Fund returned -1.04% in Q1 2026, underperforming its benchmark. Read the full analysis for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results